Cargando…

Essential complicity of perforin-granzyme and FAS-L mechanisms to achieve tumor rejection following treatment with anti-CD137 mAb

BACKGROUND: Treatment with agonist anti-CD137 (4-1BB) immunostimulatory monoclonal antibodies elicits complete tumor regressions in a number of transplanted hematological and solid malignancies in mice. Rejection is mainly dependent on cytotoxic T lymphocytes (CTL) and IFNγ, although a role for NK c...

Descripción completa

Detalles Bibliográficos
Autores principales: Morales-Kastresana, Aizea, Catalán, Elena, Hervás-Stubbs, Sandra, Palazón, Asis, Azpilikueta, Arantza, Bolaños, Elixabet, Anel, Alberto, Pardo, Julián, Melero, Ignacio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987045/
https://www.ncbi.nlm.nih.gov/pubmed/24764534
http://dx.doi.org/10.1186/2051-1426-1-3
_version_ 1782311821556842496
author Morales-Kastresana, Aizea
Catalán, Elena
Hervás-Stubbs, Sandra
Palazón, Asis
Azpilikueta, Arantza
Bolaños, Elixabet
Anel, Alberto
Pardo, Julián
Melero, Ignacio
author_facet Morales-Kastresana, Aizea
Catalán, Elena
Hervás-Stubbs, Sandra
Palazón, Asis
Azpilikueta, Arantza
Bolaños, Elixabet
Anel, Alberto
Pardo, Julián
Melero, Ignacio
author_sort Morales-Kastresana, Aizea
collection PubMed
description BACKGROUND: Treatment with agonist anti-CD137 (4-1BB) immunostimulatory monoclonal antibodies elicits complete tumor regressions in a number of transplanted hematological and solid malignancies in mice. Rejection is mainly dependent on cytotoxic T lymphocytes (CTL) and IFNγ, although a role for NK cells and dendritic cells has been observed in some tumor models. Rejection of EG7-derived thymomas has been shown to be CTL-dependent but not NK-dependent. FINDINGS: In this therapeutic setting, we show that both the perforin-granzyme and FasL effector systems are readily expressed by CD8(+) T lymphocytes infiltrating the EG7 lymphomas which are undergoing rejection. Using knock-out mice, we demonstrate that both effector cytolytic systems are involved in the execution of complete immune rejections against EG7 established tumors. In accordance, EG7 tumor cells were susceptible in vitro to both killing mechanisms acting in a synergistic fashion. CONCLUSIONS: CD137-elicited rejection of EG7-derived tumors involves the interplay of at least two final effector cytolytic mechanisms that act in cooperation.
format Online
Article
Text
id pubmed-3987045
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-39870452014-04-17 Essential complicity of perforin-granzyme and FAS-L mechanisms to achieve tumor rejection following treatment with anti-CD137 mAb Morales-Kastresana, Aizea Catalán, Elena Hervás-Stubbs, Sandra Palazón, Asis Azpilikueta, Arantza Bolaños, Elixabet Anel, Alberto Pardo, Julián Melero, Ignacio J Immunother Cancer Short Report BACKGROUND: Treatment with agonist anti-CD137 (4-1BB) immunostimulatory monoclonal antibodies elicits complete tumor regressions in a number of transplanted hematological and solid malignancies in mice. Rejection is mainly dependent on cytotoxic T lymphocytes (CTL) and IFNγ, although a role for NK cells and dendritic cells has been observed in some tumor models. Rejection of EG7-derived thymomas has been shown to be CTL-dependent but not NK-dependent. FINDINGS: In this therapeutic setting, we show that both the perforin-granzyme and FasL effector systems are readily expressed by CD8(+) T lymphocytes infiltrating the EG7 lymphomas which are undergoing rejection. Using knock-out mice, we demonstrate that both effector cytolytic systems are involved in the execution of complete immune rejections against EG7 established tumors. In accordance, EG7 tumor cells were susceptible in vitro to both killing mechanisms acting in a synergistic fashion. CONCLUSIONS: CD137-elicited rejection of EG7-derived tumors involves the interplay of at least two final effector cytolytic mechanisms that act in cooperation. BioMed Central 2013-05-29 /pmc/articles/PMC3987045/ /pubmed/24764534 http://dx.doi.org/10.1186/2051-1426-1-3 Text en Copyright © 2013 Morales-Kastresana et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Report
Morales-Kastresana, Aizea
Catalán, Elena
Hervás-Stubbs, Sandra
Palazón, Asis
Azpilikueta, Arantza
Bolaños, Elixabet
Anel, Alberto
Pardo, Julián
Melero, Ignacio
Essential complicity of perforin-granzyme and FAS-L mechanisms to achieve tumor rejection following treatment with anti-CD137 mAb
title Essential complicity of perforin-granzyme and FAS-L mechanisms to achieve tumor rejection following treatment with anti-CD137 mAb
title_full Essential complicity of perforin-granzyme and FAS-L mechanisms to achieve tumor rejection following treatment with anti-CD137 mAb
title_fullStr Essential complicity of perforin-granzyme and FAS-L mechanisms to achieve tumor rejection following treatment with anti-CD137 mAb
title_full_unstemmed Essential complicity of perforin-granzyme and FAS-L mechanisms to achieve tumor rejection following treatment with anti-CD137 mAb
title_short Essential complicity of perforin-granzyme and FAS-L mechanisms to achieve tumor rejection following treatment with anti-CD137 mAb
title_sort essential complicity of perforin-granzyme and fas-l mechanisms to achieve tumor rejection following treatment with anti-cd137 mab
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987045/
https://www.ncbi.nlm.nih.gov/pubmed/24764534
http://dx.doi.org/10.1186/2051-1426-1-3
work_keys_str_mv AT moraleskastresanaaizea essentialcomplicityofperforingranzymeandfaslmechanismstoachievetumorrejectionfollowingtreatmentwithanticd137mab
AT catalanelena essentialcomplicityofperforingranzymeandfaslmechanismstoachievetumorrejectionfollowingtreatmentwithanticd137mab
AT hervasstubbssandra essentialcomplicityofperforingranzymeandfaslmechanismstoachievetumorrejectionfollowingtreatmentwithanticd137mab
AT palazonasis essentialcomplicityofperforingranzymeandfaslmechanismstoachievetumorrejectionfollowingtreatmentwithanticd137mab
AT azpilikuetaarantza essentialcomplicityofperforingranzymeandfaslmechanismstoachievetumorrejectionfollowingtreatmentwithanticd137mab
AT bolanoselixabet essentialcomplicityofperforingranzymeandfaslmechanismstoachievetumorrejectionfollowingtreatmentwithanticd137mab
AT anelalberto essentialcomplicityofperforingranzymeandfaslmechanismstoachievetumorrejectionfollowingtreatmentwithanticd137mab
AT pardojulian essentialcomplicityofperforingranzymeandfaslmechanismstoachievetumorrejectionfollowingtreatmentwithanticd137mab
AT meleroignacio essentialcomplicityofperforingranzymeandfaslmechanismstoachievetumorrejectionfollowingtreatmentwithanticd137mab